anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a cross-sectional study in patients with asthma and healthy controls in which we will analyze markers of inflammation in blood and in induced sputum for the purpose of identifying molecular markers of specific asthma phenotypes. Our specific interest in demonstrating that periostin levels are higher than normal in blood. We already have solid preliminary data to support this hypothesis, and our goal here is to replicate preliminary findings and extend them by examining further the characteristics of the asthma subgroup with elevated periostin levels. In this regard, we propose detailed phenotyping of the asthmatic subjects and the healthy controls, including measures in induced sputum, exhaled air and detailed physiologic measures including measures of airflow, lung volumes, and methacholine responsiveness. In earlier work we have found that periostin is a marker of Th-2 driven asthma, and we will use the data collected here to further explore this possibility. The biospecimens collected here will also allow us to expand existing plasma, DNA, RNA, and sputum samples in the UCSF Airway tissue bank, so that we can continue to build this resource for future research questions.
Mitochondrial dysfunction and necrotic apoptosis, pivotal in therapeutic strategies for multiple diseases, lack comprehensive understanding in the context of renal clear cell carcinoma (ccRCC). This study explores their potential as valuable tools for ccRCC prediction, prevention, and personalized medical care. Transcriptomic and clinical datasets were acquired from the Cancer Genome Atlas (TCGA) repository. Mitochondrial and necrosis-associated gene sets were sourced from MitoCarta3.0 and the KEGG Pathway databases, respectively. Six necrosis-related mitochondrial genes (nc-MTGs) with prognostic significance were analyzed and screened, and a prognostic model was constructed. The accuracy of the model was verified using external data (E-MTAB-1980). TISCH was used to explore nc-MTGs at the cellular level. Finally, the expression level of BH3 interacting domain death agonist (BID) in ccRCC cell line was detected by real-time fluorescence quantitative polymerase chain reaction (RT-qPCR), and the effect of BID down-regulation on tumor cell migration was verified by transwell assays and wound-healing experiments. We established and validated a prognostic model for clear cell renal cell carcinoma (ccRCC) utilizing six necrosis-related mitochondrial genes (nc-MTGs), affirming its efficacy in evaluating tumor progression. RT-PCR results showed that BID expression was up-regulated in ccRCC tissues compared with controls and exhibited oncogenic effects. In vitro cell function experiments showed that BID may be an important factor affecting the migration of ccRCC. Our study is the first to elucidate the biological functions and prognostic significance of mitochondrial molecules related to necroptosis, providing a new way to evaluate mitochondrial therapeutics in patients with ccRCC.
A vaccine (A) against the effects of infection, in humans or animals is new and comprises a modified polypeptide (I) containing at least part of an envelope protein of a pathogenic retrovirus (B). (I) can enter a target cell via a membrane receptor for a host protein (HP) A vaccine (A) against the effects of infection, in humans or animals is new and comprises a modified polypeptide (I) containing at least part of an envelope protein of a pathogenic retrovirus (B). (I) can enter a target cell via a membrane receptor for a host protein (HP). The part of the envelope protein in (I) includes at least a fragment of an immunodominant zone (IZ) and contains at least one amino acid (aa) that is conserved in IZ and present in the pathogenic strain of (B). When unmodified, the polypeptide induces an immune response against both IZ and HP, and (I) induces such a response against IZ only. Independent claims are also included for the following:  (1) antibodies (Ab) obtained by immunization with (A); and  (2) nucleic acid (II) encoding (I); and  (3) expression vectors containing (II).
Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy for treatment-resistant depression. The approved method for treatment is 10Hz stimulation for 40 minutes over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been very successful in real-world situations. The limitations of this approach include the duration of the treatment (approximately 40 minutes per treatment session over 4-6 weeks). Recently, researchers have modified the treatment parameters to reduce treatment times with some preliminary success. In a recent study, an accelerated paradigm showed a significant antidepressant effect (90% remission rate) in individuals with treatment-resistant depression (TRD), in only 5 days. Additionally, 5 participants from this study carried a bipolar diagnosis and responded similarly, with no adverse events experienced or manic/hypomanic conversion observed during the treatment series. In parallel to this, evidence in the literature shows that right prefrontal rapid TMS is safe and efficacious in the treatment of bipolar mania showing laterality opposed to the proposed effect of rapid TMS in depression.

The current trial intends to utilise this modified design, i.e., an accelerated theta burst stimulation treatment over the right prefrontal cortex, for manic episodes in bipolar disorder. The trial also aims to look at the change in clinical measures and neuroimaging biomarkers.
Solutions in organic solvents of solid substances for medicinal, disinfectant and cosmetic purposes are absorbed in compositions obtained by combining higher fatty acids such as stearic acid and bases such as ammonia, caustic soda or potash and the mixture is introduced into containers such as tubes, preferably provided with filters, from which the solution is obtained by pressure, leaving behind the fatty acid salt skeleton. Aldehydes and ketones may be added and are stated to allow a reduction in the quantity of fatty acid salt necessary. Specifications 340,575 and 370,392 are referred to.  The Specification as open to inspection under Sect. 91 includes examples in which ethyl alcohol, heptane, benzine and hexane are employed as solvents and acetone, decahydronaphthalene, pyridine, acetic ether, acetophenone, chlorthymol, camphor, benzaldehyde and paraffinum liquidum are dissolved substances.  This subject-matter does not appear in the Specification as accepted.ALSO:Solutions in organic solvents of solid substances for medicinal, disinfectant and cosmetic purposes are absorbed in compositions obtained by combining higher fatty acids such as p  stearic acid and bases such as ammonia, caustic soda or potash (soaps) and the mixture is introduced into containers such as tubes, preferably provided with filters, from which the solution of the solid agent is obtained by pressure, leaving behind the fatty acid salt skeleton.  Aldehydes and ketones may be added and are stated to allow a reduction in the quantity of fatty acid salt necessary.  Examples describe the absorption in an ammonium stearate skeleton of a solution of chlorocarvacrol in hexane and acetone, thymol in chloroform and camphor in acetone. Specifications 340,575 and 370,392, [both in Group III], are referred to.  The Specification as open to inspection under Sect. 91 includes examples in which ethyl alcohol, heptane, benzine, and hexane are employed as solvents and acetone decahydronaphthalene, pyridine, acetic ether, acetaphenone, chlorthymol, camphor, benzaldehyde and paraffinum liquidum are dissolved substances.  This subject-matter does not appear in the Specification as accepted.
This study aimed to explore the organ-protective effects of dexmedetomidine in patients with sepsis combined with myocardial injury. From December 2021 to December 2023, 263 sepsis patients with myocardial injury were included based on inclusion and exclusion criteria. They were divided into an experimental group (n = 122), who had previously received dexmedetomidine, and a control group (n = 141), who had received midazolam. After matching baseline characteristics, the treatment outcomes between the 2 groups were compared. In a propensity score-matched cohort of 263 patients, each group had 62 individuals with balanced baseline characteristics. The experimental group showed significantly lower heart rates on days 1, 3, and 7 compared to the control (P < .05). Biomarkers high-sensitivity troponin I and creatine kinase-MB decreased significantly by days 3 and 7, with lower levels in the experimental group. B-type natriuretic peptide levels were also lower in the experimental group on days 3 and 7. Heart function improved in both groups, with the experimental group showing better outcomes. Inflammatory markers decreased significantly after 7 days, with the experimental group having lower levels. Hospitalization duration was similar between groups. Dexmedetomidine reduces heart rate and inflammatory markers, protects myocardial cells, and improves cardiac function in patients with sepsis and myocardial injury. It shows potential as a treatment option, with future research needed to assess its long-term efficacy and safety.
Microfluidic chips are valuable tools for studying intricate cellular and cell-microenvironment interactions. Traditional in vitro cancer models lack accuracy in mimicking the complexities of in vivo tumor microenvironment. However, cancer-metastasis-on-a-chip (CMoC) models combine the advantages of 3D cultures and microfluidic technology, serving as powerful platforms for exploring cancer mechanisms and facilitating drug screening. These chips are able to compartmentalize the metastatic cascade, deepening the understanding of its underlying mechanisms. This article provides an overview of current CMoC models, focusing on distinctive models that simulate invasion, intravasation, circulation, extravasation, and colonization, and their applications in drug screening. Furthermore, challenges faced by CMoC and microfluidic technologies are discussed, while exploring promising future directions in cancer research. The ongoing development and integration of these models into cancer studies are expected to drive transformative advancements in the field.
This study will run twice a week over 6 weeks with 6 REACH sessions optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
This interventional study investigates the modulatory effect of slow breathing with prolonged exhalation (i.e., ProlEx breathing) on decision-making under risk. Using functional magnetic resonance imaging (fMRI), the researchers seek to identify brain regions influenced by the breathing intervention during the decision-making task.

Sixty healthy participants will be invited to perform ProlEx breathing during a risky decision-making task. After initial preparations, each individual's spontaneous breathing rhythm will be determined (i.e., Eupnea, control condition). This step is to i) ensure a natural breathing pace for each participant and ii) incorporate cue-assisted breathing into the control condition to allow comparability across conditions. To further investigate the effect of ProlEx on sympathovagal tone, physiological measures of respiration, electrocardiogram, pulse, electrodermal activity, and pupil are acquired. During scanning, the participant will perform a decision-making task based on the paradigm by Tom et al. (2007). The breathing intervention is applied simultaneously with continuous cue-assisted breathing for both conditions (Eupnea, ProlEx) throughout the duration of the task. The experiment follows a block design with counterbalanced orders to control for confounding effects. After completion of the scans, the participants fill out additional questionnaires.
Traditional physiotherapy applications (Hotpack + US (Ultrasound) + TENS (Transcutaneous Electrical Stimulation) were applied to the control group initially, as in every group. After these applications, they were evaluated in terms of basic parameters. A re-evaluation was made after 12 weeks.
BACKGROUND: Multiple hippocampal transection (MHT) is a surgical technique used for the treatment of drug-resistant mesial temporal lobe epilepsy in situations where standard procedures would pose a high risk for memory deterioration. During MHT, the longitudinal fibers of the hippocampus, implicated in epilepsy spreading, are interrupted, while the transverse memory circuits are spared. The extent of MHT is governed by intraoperative electrocorticography; abolition of epileptic discharges serves as an end point to terminate the transection. In other words, the aim of MHT is not the anatomical completeness of hippocampal transection. In contrast, we hypothesize that only the complete transection of hippocampal cross-section is needed to durably terminate epilepsy, avoiding possible postoperative reorganization of longitudinal pathways. Here, we report an anatomical study designed to evaluate the feasibility of complete transection of hippocampus with the aid of ultrasound neuronavigation and we propose new instruments to reach this goal.
METHODS: Five cadaveric brains were analyzed in this study. MHT was performed on both sides of each brain either with or without ultrasound neuronavigation. The percentage of transected cross-section of the hippocampus was measured using magnetic resonance imaging (MRI) and both sides were compared.
RESULTS: The ultrasound-guided MHTs were more likely to achieve complete hippocampal transection compared with the nonnavigated MHT transection (73 vs 58%; p < 0.01). Our study also allowed us to propose specialized transectors to minimize invasivity of this procedure.
CONCLUSION: Completeness of MHT can be better reached with the aid of an ultrasound neuronavigation system; modified instruments for this procedure were also designed.
FIELD: organic chemistry. SUBSTANCE: invention relates to nonionic cellulose esters with improved thickening effect and they can be used in paint and varnish composites. Nonionic cellulose ester shows DV-viscosity value 15-200 mPa x s and comprises modifying hydrophobic group of the formula:   wherein R means aliphatic group with 12-22 carbon atoms; n = 3-7 at substitution degree of hydrophobic group 0.003-0.012. Cellulose ester can represents modified water- soluble alkylcellulose, hydroxyalkylcellulose, alkylhydroxyalkylcellulose, methylhydroxyethylcellulose, ethylhydroxyethylcellulose, methylethylhydroxyethylcellulose or hydroxyethylcellulose. Cellulose ester is designated for using as colloidal stabilizing agent, thickening agent or viscosity modifying agent. Invention relates also to paint and varnish composite comprising film-forming latex and an aqueous phase thickened with nonionic cellulose ester. Invention provides the enhancement of thickening ability of cellulose esters in paint and varnish composites. EFFECT: valuable properties of composite. 11 cl, 2 tbl, 11 ex
A smart medical box comprises a physiological measurement unit, a measuring terminal, a transmission unit, a power unit, a server, a storage unit, a comparison unit for, and an external input terminal. The measuring terminal is for a user, wherein the user has an identification part, and wherein the identification part has a sensor code. The measurement terminal comprises a sensing unit for the user to sense the identification piece to activate the physiological measurement unit to generate a physiological signal, and to measure a value as a detection signal. The transmission unit is for transmitting the detection signal. The power unit is for providing power to the sensing unit, the physiological measurement unit and the transmission unit. The server comprises a transmission module for receiving the detection signal. The storage unit is for storing the sensing code and the physiological signal. The comparison unit is for comparing whether the sensing code already exists in the storage unit. If yes, the storage unit stores the physiological signal corresponding to the sensing code. If not, the storage unit creates a new data comprising the sensor code and the physiological signal according to the sensor code, and registers the new data. The external input terminal is connected to the server terminal to register the new data.
Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to "Delayed Intervention" Arm in which case they will receive delayed intervention at 6 months.
The study aimed to show the potential clinical application of supplements used among sportsmen for patients suffering from Intensive Care Unit-acquired Weakness (ICUAW) treatment. ICUAW is a common complication affecting approximately 40% of critically ill patients, often leading to long-term functional disability. ICUAW comprises critical illness polyneuropathy, critical illness myopathy, or a combination of both, such as critical illness polyneuromyopathy. Muscle degeneration begins shortly after the initiation of mechanical ventilation and persists post-ICU discharge until proteolysis and autophagy processes normalize. Several factors, including prolonged bedrest and muscle electrical silencing, contribute to muscle weakness, resulting from an imbalance between protein degradation and synthesis. ICUAW is associated with tissue hypoxia, oxidative stress, insulin resistance, reduced glucose uptake, lower adenosine triphosphate (ATP) formation, mitochondrial dysfunction, and increased free-radical production. Several well-studied dietary supplements and pharmaceuticals commonly used by athletes are proven to prevent the aforementioned mechanisms or aid in muscle building, regeneration, and maintenance. While there is no standardized treatment to prevent the occurrence of ICUAW, nutritional interventions have demonstrated the potential for its mitigation. The use of ergogenic substances, popular among muscle-building sociates, may offer potential benefits in preventing muscle loss and aiding recovery based on their work mechanisms.
There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the "experimental phase" of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the "Xpert package" in this protocol.
The title of the invention of this disclosure is "system and method for detecting or predicting major depressive disorder recurrence". The present invention provides a system and computer-implemented method for detecting depressive recurrence in a patient. The system includes a wearable device configured to detect movement of a patient and to generate body motion record data corresponding to the movement of the patient, and a computing device for retrieving the body motion record data from the device. The system and method obtains training data, including training actigraphy data, over a training period and trains an anomaly detector using the training data. The system and method then obtains test data from the patient, extracts a plurality of features from the test data, and analyzes the extracted data using a trained anomaly detector. A self-reporting test is used to determine whether an abnormality identified by the abnormality detector indicates that the patient is likely to experience a recurrence of depression.
This is a prospective study. The study population will consist of 2 groups. The first group (PE Group) will consist of patients presenting to the Johns Hopkins All Children's Hospital (JHACH) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of JHACH undergoing CT chest for indications other than chest wall deformity. Clinical caliper measurements will be taken and used to calculate the Clinical PI.

The steps to obtain the clinical caliper measurements are as follows: With the subject lying down, a ruler will be placed across the chest and a second ruler will be used to measure the depth at the deepest point of the sternum. The 2nd ruler will then be used to measure the height of the horizontal ruler to the bed on both sides. All measurements will be made on end expiration. With the subject standing, a measuring tape will be placed around the chest at the point of the deepest sternal depression. The sternum, spine and the bilateral lateral chest locations will be marked with temporary ink. The tape will be kept as level as possible. Chest calipers will be used to measure from deepest point of sternum to posterior midline, posterior midline to anterior chest and the transverse chest diameter. Each measurement will be taken at end expiration. The circumference of the chest will be recorded.

Each set of measurements will be taken by 2 independent members of the research team. Attempts will be made to record the amount of time it takes to obtain the measurements. Consent will be obtained to photograph the process for illustrative purposes. Every attempt will be made to conceal the patient's identity by excluding the face from the photograph. In instances where the face is not able to be excluded, the facial features will be blurred.

Clinical measurements may be recorded during routine medical care at the provider's discretion. However, these measurements will be considered research procedures for the purposes of this trial. A copy of the measurements will be placed in the medical chart of subjects evaluated for PE for the provider's future reference. Measurements obtained in the Control group will be strictly for the purposes of the research protocol. All subjects, regardless of group, will be provided standard of care for all other medical conditions.

All CT and MRI performed for both PE and Control groups will be reviewed and the PI will be determined by a single, blinded radiologist. The radiologist determining the PI may not be the interpreting radiologist and will have no responsibility to provide a comprehensive interpretation of the study. The PI as determined by the research radiologist will be recorded separately from the subject's EMR in a research file. Having a single, blinded radiologist determine the PI for the entire research cohort will allow for consistency in determining the PI, as this is the gold standard to which we are comparing our clinical measurements.